Apazunersen

N/A

Report date: 2026/02/28 20:00:37
NME

Base Information

Drug NameApazunersen
Drug Alias NameGTX-102
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionUbiquitin-like modifier-activating enzyme 3A stimulants
TargetsUbiquitin-like modifier-activating enzyme 3A
Therapy Area/IndicationsAngelman SyndromeAtaxia Telangiectasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[14] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTexas A&M Agrilife ResearchTexas A&M University
China Registration ClassN/A

Develop Information

Active CompaniesUltragenyx Pharmaceutical Inc
Inactive CompaniesGrace Therapeutics Inc
Active IndicationsAngelman Syndrome
Inactive IndicationsAtaxia Telangiectasia

Other Information

ATC CodeN/A
Related LinksN/A